Blog
RSS FeedPosted by Michael Wonder on 01 Apr 2020
Coronavirus Treatment Acceleration Program
1 April 2020 - FDA has created a special emergency program for possible therapies, the Coronavirus Treatment Acceleration Program. ...
Posted by Michael Wonder on 24 Mar 2020
Samsung Bioepis announces FDA approval of 420 mg multi-dose vial of Ontruzant (trastuzumab-dttb)
24 March 2020 - 150 mg and 420 mg vial of Ontruzant are now approved. ...
Posted by Michael Wonder on 24 Mar 2020
U.S. FDA approves supplemental new drug application for expanded indication of Eucrisa (crisaborole) 2% ointment in children as young as 3 months of age with mild-to-moderate atopic dermatitis
24 March 2020 - Eucrisa is the first and only 100% steroid-free, topical prescription medication approved for patients as young as ...
Posted by Michael Wonder on 24 Mar 2020
Biosimilar pegfilgrastim on the PBS - information for health professionals and patients
24 March 2020 - The first biosimilar brand of pegfilgrastim (Ziextenzo) has listed on the PBS on 1 March 2020. ...
Posted by Michael Wonder on 24 Mar 2020
The drug helping coronavirus patients
24 March 2020 - A flash of potential good news from the front lines of the coronavirus pandemic: ...
Posted by Michael Wonder on 24 Mar 2020
An update on the 2020 annual meeting in Beijing, China
20 March 2020 - Based on the balance of the evidence before the Board, and with the strong support of our ...
Posted by Michael Wonder on 24 Mar 2020
Dentists banned from prescribing potential COVID-19 drug to self, family
24 March 2020 - The Australian government has rushed through an emergency regulation banning dentists from prescribing an arthritis drug ...
Posted by Michael Wonder on 24 Mar 2020
COVID-19: hydroxychloroquine
24 March 2020 - There has been a lot of interest around the use of hydroxychloroquine for treatment of COVID-19 ...
Posted by Michael Wonder on 24 Mar 2020
Helsinn announces European approval of the IV formulation of Akynzeo (fosnetupitant with palonosetron)
23 March 2020 - Helsinn today announces that the European Commission has approved the intravenous formulation of Akynzeo, (a fixed ...
Posted by Michael Wonder on 24 Mar 2020
Edaravone for amyotrophic lateral sclerosis: barriers to access and lifeboat ethics
23 March 2020 - Despite its unavailability in Canada, patients legally imported the drug under provisions of the Canadian Food and ...
Posted by Michael Wonder on 23 Mar 2020
EMA publishes agenda for 23-26 March CHMP meeting
23 March 2020 - The EMA has published a draft agenda for this week's CHMP meeting. ...
Posted by Michael Wonder on 23 Mar 2020
Rush to raise funds for large COVID-19 drug trial in Australian hospitals
23 March 2020 - Australian researchers behind a new clinical trial of two drugs to treat COVID-19 are desperate to ...
Posted by Michael Wonder on 23 Mar 2020
COVID-19 and processing times
23 March 2020 - At present, TLV's operations continue as usual. ...
Posted by Michael Wonder on 23 Mar 2020
Eiger BioPharmaceuticals completes submission of new drug application to FDA for lonafarnib for treatment of progeria and progeroid laminopathies
23 March 2020 - Progeria MAA submitted to EMA and granted accelerated assessment. ...
Posted by Michael Wonder on 23 Mar 2020
Intra-Cellular prices schizophrenia drug at $1,320 per month
23 March 2020 - Intra-Cellular Therapies said on Monday its lead drug to treat schizophrenia was now available at U.S. ...
Posted by Michael Wonder on 23 Mar 2020
FDA and EMA collaborate to facilitate SARS-CoV-2 vaccine development
23 March 2020 - Vaccines offer a way to build immunity to a disease-causing microorganism before one has ever been exposed ...